Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study

Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study

<p><strong>Objectives:</strong> To investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of nipocalimab in participants with moderate to severe active rheumatoid arthritis (RA) and inadequate response or intolerance to ≥1 antitumour necrosis factor agent.</p>...

Full description

Bibliographic Details
Main Authors: Taylor, PC, Schett, G, Huizinga, TW, Wang, Q, Ibrahim, F, Zhou, B, Liva, SG, Shaik, JSB, Xiong, Y, Leu, JH, Panchakshari, RA, Loza, MJ, Ma, K, Dhatt, H, Rojo Cella, R, Karyekar, CS, Cuff, CA, Gao, S, Fei, K
Format: Journal article
Language:English
Published: BMJ Publishing Group 2024

Similar Items